Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author AMICIS, Karine M. De FMUSP-HC
BARROS, Samar Freschi de FMUSP-HC
ALENCAR, Raquel E. FMUSP-HC
POSTOL, Edilberto FMUSP-HC
MARTINS, Carlo de Oliveira FMUSP-HC
ARCURI, Helen Andrade FMUSP-HC
GOULART, Cibelly
KALIL, Jorge FMUSP-HC
GUILHERME, Luiza FMUSP-HC
dc.date.issued 2014
dc.identifier.citation VACCINE, v.32, n.32, p.4104-4110, 2014
dc.identifier.issn 0264-410X
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/7364
dc.description.abstract Streptococcus pyogenes is responsible for infections as pharyngitis, sepsis, necrotizing fasciitis and streptococcal toxic shock syndrome. The M protein is the major bacterial antigen and consists of both polymorphic N-terminal portion and a conserved region. In the present study, we analyzed the in vitro ability of StreptInCor a C-terminal candidate vaccine against S. pyogenes to induce antibodies to neutralize/opsonize the most common S. pyogenes strains in Sao Paulo by examining the recognition by sera from StreptInCor immunized mice. We also evaluated the presence of cross-reactive antibodies against human heart valve tissue. Anti-StreptInCor antibodies were able to neutralize/opsonize at least 5 strains, showing that immunization with StreptInCor is effective against several S. pyogenes strains and can prevent infection and subsequent sequelae without causing autoimmune reactions.
dc.description.sponsorship · Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
· Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
· Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
dc.language.iso eng
dc.publisher ELSEVIER SCI LTD
dc.relation.ispartof Vaccine
dc.rights restrictedAccess
dc.subject Streptococcus pyogenes; Vaccine; Rheumatic fever; Immunization coverage; Immune response
dc.subject.other rheumatic heart-disease; proteins; pathogenesis; infections; fever
dc.title Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes
dc.type article
dc.rights.holder Copyright ELSEVIER SCI LTD
dc.description.group LIM/19
dc.description.group LIM/58
dc.description.group LIM/60
dc.identifier.doi 10.1016/j.vaccine.2013.08.043
dc.identifier.pmid 23994376
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author AMICIS, Karine M. De:FM:
hcfmusp.author BARROS, Samar Freschi de:HC:LIM/19
hcfmusp.author ALENCAR, Raquel E.:HC:LIM/19
hcfmusp.author POSTOL, Edilberto:HC:LIM/19
hcfmusp.author MARTINS, Carlo de Oliveira:FM:
hcfmusp.author ARCURI, Helen Andrade:FM:
hcfmusp.author KALIL, Jorge:FM:MCM
hcfmusp.author GUILHERME, Luiza:HC:LIM/19
hcfmusp.author.external · GOULART, Cibelly:Butantan Inst, Ctr Biotechnol, Sao Paulo, Brazil
hcfmusp.origem.id WOS:000339146900014
hcfmusp.origem.id 2-s2.0-84902553232
hcfmusp.publisher.city OXFORD
hcfmusp.publisher.country ENGLAND
hcfmusp.relation.reference · Barbosa PJB, 2009, ARQ BRAS CARDIOL, V93, P1
· Bessen DE, 2000, J INFECT DIS, V182, P1109, DOI 10.1086/315842
· Bisno AL, 2003, LANCET INFECT DIS, V3, P191, DOI 10.1016/S1473-3099(03)00576-0
· Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
· Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
· Dale JB, 2013, VACCINE, V31, pB216, DOI 10.1016/j.vaccine.2012.09.045
· Dale JB, 2013, VACCINE, V31, P1576, DOI 10.1016/j.vaccine.2013.01.019
· Goulart C, 2011, VACCINE, V29, P1634, DOI 10.1016/j.vaccine.2010.12.074
· Guerino MT, 2011, VACCINE, V29, P8250, DOI 10.1016/j.vaccine.2011.08.113
· GUILHERME L, 1995, CIRCULATION, V92, P415
· Guilherme L, 2011, UPDATE GLOMERULOPATH
· Guilherme L, 2006, CLIN DEV IMMUNOL, V13, P125, DOI 10.1080/17402520600877026
· Guilherme L, 2011, J BIOL CHEM, V286, P6989, DOI 10.1074/jbc.M110.132118
· Guilherme L, 2011, Ann Pediatr Cardiol, V4, P13, DOI 10.4103/0974-2069.79617
· Guilherme L, 2009, METHODS, V49, P316, DOI 10.1016/j.ymeth.2009.03.024
· Guilherme L, 2006, AUTOIMMUNITY, V39, P31, DOI 10.1080/08916930500484674
· Guilherme L, 2011, S PYOGENES INFECT IT, P468
· LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
· McGregor KF, 2004, J BACTERIOL, V186, P4285, DOI 10.1128/JB.186.13.4285-4294.2004
· McMillan DJ, 2013, CLIN MICROBIOL INFEC, V19, pE222, DOI 10.1111/1469-0691.12134
· McMillan DJ, 2012, AUTHORS CLIN MICROBI, V5, P222
· McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458
· Narula J, 1999, RHEUMATIC FEVER
· Postol E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060969
· Shulman ST, 2009, CLIN INFECT DIS, V49, P78, DOI 10.1086/599344
· Smeesters PR, 2010, TRENDS MICROBIOL, V18, P275, DOI 10.1016/j.tim.2010.02.007
· Smeesters PR, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000010
· Smeesters PR, 2009, EXPERT REV VACCINES, V8, P1705, DOI [10.1586/erv.09.133, 10.1586/ERV.09.133]
· Smeesters PR, 2008, VACCINE, V26, P5835, DOI 10.1016/j.vaccine.2008.08.037
· Steer AC, 2013, PEDIATR INFECT DIS J, V32, P180, DOI 10.1097/INF.0b013e318281da11
· Steer AC, 2009, LANCET INFECT DIS, V9, P611, DOI 10.1016/S1473-3099(09)70178-1
· Steer AC, 2009, CURR OPIN INFECT DIS, V22, P544, DOI 10.1097/QCO.0b013e328332bbfe
· Tartof SY, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-327
· TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
dc.description.index MEDLINE
dc.identifier.eissn 1873-2518
hcfmusp.citation.scopus 17
hcfmusp.citation.wos 16
hcfmusp.affiliation.country Brasil


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics